Isavuconazole for invasive mold disease in patients with hematological malignancies: a multicenter real-world study from China on efficacy, safety, and competing risks
Antimicrobial Agents and Chemotherapy · 05.08.2026 · 70 (8)
DOI: 10.1128/aac.00543-26 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 05.08.2026. Verfasst von Jirui Zhang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The Fifth People's Hospital of Suzhou/The Affiliated Infectious Diseases Hospital, Suzhou Medical College of Soochow Universi…. Hauptthemen laut MEDLINE: Triazoles, Pyridines, Antifungal Agents, Hematologic Neoplasms. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hospital Pharmacy Research Grant from Jiangsu Provincial Pharmaceutical Association - Aosaikang.
Abstract (Originalsprache)
Isavuconazole is approved for invasive aspergillosis (IA) and mucormycosis, but real-world data in patients with hematological malignancies are limited. This retrospective study (2022–2025) included adult patients with hematological malignancies and proven/probable invasive mold disease (IMD) who were treated with isavuconazole for ≥72 h at two Chinese hospitals. The primary endpoint was week 6 treatment success (survival, clinical/radiological improvement, and no discontinuation due to failure/toxicity). Secondary endpoints included all-cause and IMD-attributable mortality at weeks 6 and 12 (competing risk analysis). Among 84 patients, 62 had aspergillosis (69.4% treatment success), 14 had mucormycosis (35.7%), and 8 had mixed infection (25.0%); the overall week 6 treatment success was 59.5% (50/84), with significant variation across infection types ( P = 0.007) and treatment strategy (monotherapy 65.6% vs. combination 43.5%; P < 0.001), but not by therapy role. Week 6 all-cause and IMD-attributable mortality rates were 17.9% and 11.9%, respectively; IMD-attributable mortality rate was lower with monotherapy (6.6%) than with combination therapy (26.1%; P = 0.023). Week 12 all-cause mortality rate was 21.6%. Competing risk analysis showed significant differences in week 12 attributable mortality by infection type (overall P = 0.04): aspergillosis, 9.7%; mucormycosis, 36.0%; and mixed, 13.0%. Monotherapy was associated with lower attributable mortality than combination therapy (8.2% vs. 31.0%; P = 0.01). Four patients (4.8%) had drug-related adverse events (one discontinuation due to vomiting). In this real-world Chinese cohort, isavuconazole achieved 59.5% treatment success with favorable safety. Infection type and treatment strategy were key prognostic factors: aspergillosis and monotherapy were associated with better outcomes, whereas mucormycosis and combination therapy were associated with higher attributable mortality risk.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, The Fifth People's Hospital of Suzhou/The Affiliated Infectious Diseases Hospital, Suzhou Medical College of Soochow University, Suzhou, Jiangsu, China.
- Department of Pharmacy, The Fourth Affiliated Hospital of Soochow University (Suzhou Dushu Lake Hospital), Suzhou, Jiangsu, China.
ORCID-Profile: Hui Wang
Förderung
- Hospital Pharmacy Research Grant from Jiangsu Provincial Pharmaceutical Association - Aosaikang
Zitieren
APA
Zhang, J., Xu, M., Mao, J., Ma, J., & Wang, H. (2026). Isavuconazole for invasive mold disease in patients with hematological malignancies: a multicenter real-world study from China on efficacy, safety, and competing risks. Antimicrobial Agents and Chemotherapy, 70(8). https://doi.org/10.1128/aac.00543-26
Vancouver
Zhang J, Xu M, Mao J, Ma J, Wang H. Isavuconazole for invasive mold disease in patients with hematological malignancies: a multicenter real-world study from China on efficacy, safety, and competing risks. Antimicrobial Agents and Chemotherapy. 2026;70(8). doi:10.1128/aac.00543-26
BibTeX
@article{Zhang2026,
author = {Zhang, Jirui and Xu, Mengying and Mao, Jiaojiao and Ma, Jingjing and Wang, Hui},
title = {Isavuconazole for invasive mold disease in patients with hematological malignancies: a multicenter real-world study from China on efficacy, safety, and competing risks},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2026},
volume = {70},
number = {8},
doi = {10.1128/aac.00543-26}
}
EUVIMED